Previous 10 | Next 10 |
home / stock / entbf / entbf news
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) ( "S...
Entheon Biomedical ([[ENTBF]] +2.8%) has entered into a definitive agreement to acquire personalized genetics company Lobo Genetics.Pursuant to the agreement, the company will issue an aggregate of 5M shares to the shareholders of Lobo.Under the deal, which is structured as a three-...
Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols Vancouver, British Columbia--(Newsfile Corp. - June 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company ") is pleased to announce that th...
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"),...
Entheon Biomedical (ENTBF) has entered into a drug-supply agreement with Laboratorium Ofichem BV.Under the terms of the agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine drug substances ("DMT").Ofichem will provide GMP DMT product as well as the required analytica...
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply a...
Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened expertise focused on driving initiatives forward Upgraded OTC Listing Financial Update Vancouver, British Columbia--(Newsf...
Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) today announced that, Timothy Ko, CEO of Entheon, will be attending the Q2 Virtual Investor Summit. About Entheon Biomedical Corp. Entheon Biomedical is a drug development and ...
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been appr...
Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic ...
News, Short Squeeze, Breakout and More Instantly...
Entheon Biomedical Corp Com Company Name:
ENTBF Stock Symbol:
OTCMKTS Market:
Entheon Biomedical Corp Com Website:
2024-03-27 17:08:02 ET Addiction is an issue that affects a significant number of people worldwide. While conventional treatments have existed for decades, they offer a very low rate of efficacy, often as low as 5%. For Timothy Ko , CEO of Entheon Biomedical , the problem ...
2024-03-27 17:08:02 ET Leading-edge addiction recovery solution Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorde...
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”) , a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fel...